---
figid: PMC5501768__onc2016526f1
figlink: /pmc/articles/PMC5501768/figure/fig1/
number: Figure 1
caption: Scheme depicting mechanisms of resistance observed to BRAF and MEK1/2 inhibitors
  in vitro and in vivo. Resistance is largely mediated by alternative means of MAPK
  pathway activation. Mutations in MEK1 and MEK2 that interfere with drug binding-pockets
  or that upregulate inherent kinase activity mediate resistance to both BRAF and
  MEK inhibitors. The pathway can also be reactivated through gain-of-function NRASQ61H/K/R
  mutations, alternative splice variants of BRAFV600E, overexpression of BRAFV600E,
  CRAF or Cancer Osaka thyroid oncogene (COT1) or phosphatase and tensin homolog (PTEN)
  mutations. Overexpression of RTKs including platelet-derived growth factor receptor
  β (PDGFRβ), epidermal growth factor receptor (ERBB2), insulin-like growth factor
  1 receptor (IGFR1), hepatocyte growth factor receptor (MET) and AXL RTK have also
  been proposed to drive resistance.
pmcid: PMC5501768
papertitle: Activated MEK cooperates with Cdkn2a and Pten loss to promote the development
  and maintenance of melanoma.
reftext: H Yang, et al. Oncogene. 2017 Jul 6;36(27):3842-3851.
pmc_ranked_result_index: '36958'
pathway_score: 0.9592226
filename: onc2016526f1.jpg
figtitle: Scheme depicting mechanisms of resistance observed to BRAF and MEK1/2 inhibitors
  in vitro and in vivo
year: '2017'
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5501768__onc2016526f1.html
  '@type': Dataset
  description: Scheme depicting mechanisms of resistance observed to BRAF and MEK1/2
    inhibitors in vitro and in vivo. Resistance is largely mediated by alternative
    means of MAPK pathway activation. Mutations in MEK1 and MEK2 that interfere with
    drug binding-pockets or that upregulate inherent kinase activity mediate resistance
    to both BRAF and MEK inhibitors. The pathway can also be reactivated through gain-of-function
    NRASQ61H/K/R mutations, alternative splice variants of BRAFV600E, overexpression
    of BRAFV600E, CRAF or Cancer Osaka thyroid oncogene (COT1) or phosphatase and
    tensin homolog (PTEN) mutations. Overexpression of RTKs including platelet-derived
    growth factor receptor β (PDGFRβ), epidermal growth factor receptor (ERBB2), insulin-like
    growth factor 1 receptor (IGFR1), hepatocyte growth factor receptor (MET) and
    AXL RTK have also been proposed to drive resistance.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - PIK3CG
  - PIK3CB
  - PIK3CD
  - AXL
  - PIK3R4
  - PIK3R3
  - MAPK3
  - PIK3R6
  - PTEN
  - ERBB2
  - AKT2
  - HRAS
  - PIK3R5
  - PIK3CA
  - PDGFRB
  - NRAS
  - MAP2K1
  - AKT3
  - AKT1
  - RPTOR
  - BRAF
  - MAPK1
  - KRAS
  - MTOR
  - MET
  - CROT
  - MAP2K2
  - EGFR
  - RAF1
  - Selumetinib
  - Trametinib
  - Dabrafenib
  - Cobimetinib
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
genes:
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: Axl
  symbol: AXL
  source: hgnc_symbol
  hgnc_symbol: AXL
  entrez: '558'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: ERK1/2
  symbol: ERK1
  source: hgnc_alias_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: (PTEN
  symbol: PTEN
  source: hgnc_symbol
  hgnc_symbol: PTEN
  entrez: '5728'
- word: ERBB2
  symbol: ERBB2
  source: hgnc_symbol
  hgnc_symbol: ERBB2
  entrez: '2064'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: PDGFR-B
  symbol: PDGFRB
  source: hgnc_symbol
  hgnc_symbol: PDGFRB
  entrez: '5159'
- word: NRAS
  symbol: NRAS
  source: hgnc_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: MEK1
  symbol: MEK1
  source: hgnc_alias_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: mTORC1
  symbol: mTORC1
  source: bioentities_symbol
  hgnc_symbol: RPTOR
  entrez: '57521'
- word: BRAF
  symbol: BRAF
  source: hgnc_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: ERK1/2
  symbol: ERK2
  source: hgnc_alias_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: mTORC1
  symbol: mTORC1
  source: bioentities_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: c-MET
  symbol: MET
  source: hgnc_symbol
  hgnc_symbol: MET
  entrez: '4233'
- word: COT
  symbol: COT
  source: hgnc_alias_symbol
  hgnc_symbol: CROT
  entrez: '54677'
- word: MEK1/2
  symbol: MEK2
  source: hgnc_alias_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: EGFR
  symbol: EGFR
  source: hgnc_symbol
  hgnc_symbol: EGFR
  entrez: '1956'
- word: CRAF
  symbol: c-Raf
  source: hgnc_alias_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
chemicals:
- word: Selumetinib
  source: MESH
  identifier: C517975
- word: Trametinib
  source: MESH
  identifier: C560077
- word: Dabrafenib
  source: MESH
  identifier: C561627
- word: Cobimetinib
  source: MESH
  identifier: C574276
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Cardiomyopathy
  source: ''
  identifier: ''
- word: Lung cancer
  source: ''
  identifier: ''
- word: Noonan syndrome
  source: ''
  identifier: ''
---
